TScan Therapeutics (TCRX) Return on Capital Employed (2021 - 2026)
TScan Therapeutics' (TCRX) quarterly Return on Capital Employed came in at 65.86% in Q1 2026, down 2249.0% year-on-year from 3.06% in Q1 2025, and down 9.99% on a QoQ basis from 59.88% in Q4 2025.
TScan Therapeutics (TCRX) Return on Capital Employed (2021 - 2026) Analysis & Trends
TScan Therapeutics (TCRX) has 6 years of Return on Capital Employed data on file, last reported at 65.86% in Q1 2026.
- On a quarterly basis, Return on Capital Employed fell 2249.0% year-over-year to 65.86% in Q1 2026; TTM through Mar 2026 was 65.86%, a 2249.0% decrease from a year earlier, with the FY2025 full-year figure at 48.29%, down 109.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 65.86%, down from 59.88% in the prior quarter.
- Over the last five years, Return on Capital Employed for TCRX reached as high as 33.49% in Q3 2023 and fell as low as 65.86% in Q1 2026.
- Historically, Return on Capital Employed has averaged 44.61% across 5 years, with a median of 42.5% in 2023.
- Across the five-year window, Return on Capital Employed surged 1020 bps in 2023 and tumbled 2329 bps in 2025, its largest moves.
- Year by year, Return on Capital Employed stood at 40.39% in 2022, then advanced by 8 bps to 37.09% in 2023, then fell by 12 bps to 41.66% in 2024, then sank by 44 bps to 59.88% in 2025, then declined by 10 bps to 65.86% in 2026.
- Per Business Quant data, the three most recent Return on Capital Employed figures were 65.86% in Q1 2026, 59.88% in Q4 2025, and 59.19% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -107.40% |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 10.46% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -68.84% |
| 10 | TScan Therapeutics | 100.59 Mn | -27.47 Mn | - | -65.86% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -65.86% |
| Dec 31, 2025 | -59.88% |
| Sep 30, 2025 | -59.19% |
| Jun 30, 2025 | -50.73% |
| Mar 31, 2025 | -43.37% |
| Dec 31, 2024 | -41.66% |
| Sep 30, 2024 | -35.90% |
| Jun 30, 2024 | -41.44% |
| Mar 31, 2024 | -45.37% |
| Dec 31, 2023 | -37.09% |
| Sep 30, 2023 | -33.49% |
| Jun 30, 2023 | -39.30% |
| Mar 31, 2023 | -42.50% |
| Dec 31, 2022 | -40.39% |
| Sep 30, 2022 | -43.69% |
| Jun 30, 2022 | -42.93% |
| Mar 31, 2022 | -35.62% |
| Dec 31, 2021 | -27.77% |
| Sep 30, 2021 | -29.24% |